Trial Profile
Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2015
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide
- Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis
- Focus Therapeutic Use
- 07 Dec 2015 New trial record